Warning

Failed deleting thumb_190_70.jpg

7 Apr 2017

7 Apr 2017: EVVIVAX Visiting PennVet, Philadelphia, USA

Dr Luigi Aurisicchio, CEO at EVVIVAX and President at VITARES, is very happy to visit the School of Veterinary Medicine at the

10-12 Oct 2016

Barcelona, 10-12 October 2016: EVVIVAX will be at the World Veterinary Vaccine Meeting

News Barcellona Evvivax

6 Sep 2016

London, 6 September 2016:
EVVIVAX has participated at the meeting "Comparative Oncology: The Next Frontier?", held at Royal Veterinary College, Royal College Street, London NW1 0TU.

Evvivax News

17 feb 2022 - Applied DNA and EvviVax Announce Publication of Positive Preclinical Data for LinearDNA™ Platform Approach to Cancer Immunotherapy

- First Published Study Demonstrates LinearDNA Pan-Cancer and Colon Cancer...
7 June 2021 - Evvivax and Applied DNA Veterinary COVID-19 Vaccine Candidate Induces Neutralizing Antibodies in 100% of Trial Cohort Against B.1.1.7, P1, and B.1.526 Variants

- All 11 vaccinated felines produced neutralizing antibody titers against all...
Risultati positivi dal test di fase 1 del vaccino anti Covid sui gatti

Realizzato da un'azienda italiana, sperimentazione in Usa Ha dato un risultato positivo...
12 April 2021 – Applied DNA and Evvivax Announce Positive Preliminary Results of Phase I Clinical Trial for LinearDNA™ COVID-19 Vaccine Candidate in Felines

- Vaccine Candidate Well Tolerated and Effective in Cohort - - Strong...
Applied DNA and Evvivax Initiate Phase I of Clinical Trial to Evaluate LinearDNA™ COVID-19 Vaccine Candidate for Feline Veterinary Market

STONY BROOK, N.Y. and ROME, ITALY – March 2, 2021 - Applied DNA Sciences, Inc...
Applied DNA and Takis Biotech/Evvivax to Launch Clinical Trial for Veterinary Use of Linear COVID-19 Vaccine Candidate

STONY BROOK, N.Y. – September 16, 2020 - Applied DNA Sciences, Inc. (NASDAQ: APDN)...
Takis and Evvivax developing a 2019-nCoV Coronavirus vaccine

Rome, 27 January 2020 - Takis and Evvivax, two biotechnology companies present...
LineaRx and Takis/Evvivax Anti-Cancer Vaccine Candidates Demonstrate Tumor Reduction

Tumor Reduction Demonstrated In Vivo Using Two Linear DNA Vaccines in Animal...
2-3 July 2019 – Evvivax presents data at the University of Copenaghen

Our CEO/CSO Luigi Aurisicchio flew to Copenaghen to present promising results...
27 February – 1 March 2019 – Evvivax is a sponsor of the 1st VITARES Annual Meeting, Rome, Italy

Evvivax is glad to sponsor the first Vitares Annual Congress, which is also...
9-10 January – EVVIVAX at the UK & International Veterinary Vaccinology Network Conference, London (UK)

Dr. Antonella Conforti represents EVVIVAX at the fifth UK & International...
LineaRx signs agreement with Takis/Evvivax to develop linear-DNA based anti-cancer vaccines

Applied DNA Sciences Inc. ("Applied DNA" or the "Company") announced that...
25-29 October - EVVIVAX to present data at the Veterinary Cancer Society, Portland, Oregon (USA)

Evvivax scientists will be at VCS and present the following abstract: Tel-eVax™:...
22 Sep 2017

22 September 2017 - EVVIVAX scientists successfully treat an Asian Elephant...
10-12 Apr 2017

10-12 Apr 2017 - EVVIVAX at the World Veterinary Vaccine Conference,...
7 Apr 2017

7 Apr 2017: EVVIVAX Visiting PennVet, Philadelphia, USA Dr Luigi Aurisicchio,...
10-12 Oct 2016

Barcelona, 10-12 October 2016: EVVIVAX will be at the World Veterinary Vaccine...
6 Sep 2016

London, 6 September 2016:EVVIVAX has participated at the meeting "Comparative...

News

Engineered Veterinary Vectored Immunotherapy and Vaccines: EVVIVAX

EVVIVAX stems from new, European platform technologies, aims to offer novel therapeutic avenues to pet cancer patients, with the strong translational potential to complement current human Immune-Oncology approaches in the next future.